Compare Deere & Company (DE) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deere & Company vs Twist Bioscience Corp — how do they compare? Deere & Company trades at $652.58 (market cap $177.11B), while Twist Bioscience Corp trades at $157.83 (market cap $10.32B). The key difference: Deere & Company is far larger — about 17.2× Twist Bioscience Corp's market cap, and Deere & Company pays a 0.99% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Deere & Company for 75 Days and Twist Bioscience Corp for 27 Days on average.
| DE | TWST | |
|---|---|---|
Market Cap | $177.11B | $10.32B |
Volume | 1,206,308 | 5,894,998 |
Sector | Industrials | Health |
52-Week High | $709.48 | $205.00 |
52-Week Low | $439.11 | $25.45 |
Typical Hold Time | 75 Days | 27 Days |
Enterprise Value | $231.01B | $10.24B |
Dividend Yield | 0.99% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deere & Company (DE) trades at $652.58, down 4.42% today, showing bearish technical signals with support at $643 and resistance at $658. The company maintains strong profitability with a 10.39% net margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights Deere's AI initiatives and institutional buying interest, though revenue has declined from 2023 peaks.
Deere presents a mixed outlook with solid fundamentals and analyst support (43.48% buy rating, $731.20 target) but faces agricultural cycle headwinds and competitive pressures. The stock offers potential upside from AI-driven farming solutions but risks include cyclical demand volatility and high debt levels at 60.31% of assets.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
